We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.46B
AUM Growth
-$732M
Cap. Flow
-$476M
Cap. Flow %
-10.67%
Top 10 Hldgs %
48.58%
Holding
171
New
10
Increased
26
Reduced
81
Closed
23

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$53M
2
BEAM icon
Beam Therapeutics
BEAM
+$23M
3
SYK icon
Stryker
SYK
+$17.7M
4
ABBV icon
AbbVie
ABBV
+$17.5M
5
BAX icon
Baxter International
BAX
+$14.9M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$204M
2
ARVN icon
Arvinas
ARVN
+$45.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$34.7M
4
VRNA
Verona Pharma
VRNA
+$30.4M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$28.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Technology 0.01%
3 Communication Services 0.01%
4 Consumer Discretionary 0%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
101
10x Genomics
TXG
$5.55B
$2.02M 0.05%
230,997
-39,731
-15% -$501K
BMY icon
102
Bristol-Myers Squibb
BMY
$124B
$1.56M 0.03%
25,566
-12,547
-33% -$731K
DOCS icon
103
Doximity
DOCS
$3.87B
$1.38M 0.03%
23,816
-4,095
-15% -$259K
SMMT icon
104
Summit Therapeutics
SMMT
$10.7B
$1.31M 0.03%
67,685
-102,909
-60% -$2.06M
RDY icon
105
Dr. Reddy's Laboratories
RDY
$10.5B
$1.21M 0.03%
91,916
-5,984
-6% -$82.6K
GDX icon
106
VanEck Gold Miners ETF
GDX
$21.8B
$1.2M 0.03%
26,200
– –
RXRX icon
107
Recursion Pharmaceuticals
RXRX
$1.56B
$1.03M 0.02%
195,052
-182,754
-48% -$1.33M
SNY icon
108
Sanofi
SNY
$107B
$887K 0.02%
+16,000
New +$866K
PTGX icon
109
Protagonist Therapeutics
PTGX
$9.06B
$852K 0.02%
17,622
-6,096
-26% -$255K
RYTM icon
110
Rhythm Pharmaceuticals
RYTM
$7.31B
$824K 0.02%
15,550
-8,046
-34% -$446K
BBNX
111
Beta Bionics
BBNX
$770M
$818K 0.02%
+66,825
New +$1.25M
CERT icon
112
Certara
CERT
$1.08B
$809K 0.02%
81,740
-10,389
-11% -$126K
BNTX icon
113
BioNTech
BNTX
$23.1B
$725K 0.02%
7,964
-368
-4% -$41.2K
ZLAB icon
114
Zai Lab
ZLAB
$2.28B
$723K 0.02%
20,000
+7,000
+54% +$215K
ARQT icon
115
Arcutis Biotherapeutics
ARQT
$3.56B
$558K 0.01%
35,700
-3,800
-10% -$53.5K
ZTS icon
116
Zoetis
ZTS
$32.1B
$513K 0.01%
3,114
-6,665
-68% -$1.11M
KRYS icon
117
Krystal Biotech
KRYS
$10.5B
$478K 0.01%
2,650
-2,397
-47% -$403K
IWM icon
118
iShares Russell 2000 ETF
IWM
$81.7B
$459K 0.01%
+2,300
New +$499K
NAMS icon
119
NewAmsterdam Pharma
NAMS
$3.7B
$446K 0.01%
21,800
-3,200
-13% -$71.1K
TEVA icon
120
Teva Pharmaceuticals
TEVA
$37.3B
$445K 0.01%
28,930
-31,668
-52% -$566K
PCVX icon
121
Vaxcyte
PCVX
$8.12B
$426K 0.01%
11,290
-748
-6% -$59.8K
TVTX icon
122
Travere Therapeutics
TVTX
$5.27B
$414K 0.01%
23,100
– –
MDGL icon
123
Madrigal Pharmaceuticals
MDGL
$12.8B
$364K 0.01%
1,100
– –
BBIO icon
124
BridgeBio Pharma
BBIO
$15.9B
$360K 0.01%
10,400
– –
MRUS
125
DELISTED
Merus
MRUS
$337K 0.01%
8,000
– –
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2025 Portfolio in Review

As of Q1 2025, Bellevue Group held 171 positions worth $4.46B, down 14% from $5.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $476M in Q1 2025, closing 23 positions and reducing 81 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $204M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Bellevue Group opened a new position in Akero Therapeutics worth $50.6M.

  • Bellevue Group's largest Q1 2025 buy was Akero Therapeutics: 1,250,666 shares worth $50.6M.
  • Bellevue Group added most to Beam Therapeutics in Q1 2025, an estimated $23M increase.
  • Bellevue Group's biggest Q1 2025 reduction was Vertex Pharmaceuticals, cutting an estimated $34.7M.
  • Bellevue Group fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $204M.
  • Bellevue Group's ten largest holdings make up 49% of its $4.46B portfolio in Q1 2025.
  • Bellevue Group opened 10 new positions and closed 23 in Q1 2025.
  • Bellevue Group's portfolio value fell 14% quarter-over-quarter to $4.46B.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.